Minimally Invasive Prostatic Vapor Ablation for the Treatment of BPH in Large Prostates (Rezūm XL)

Not Applicable

Terminated

• Conditions: BPH; BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms; BPH With Urinary Obstruction
• Interventions: Device: Prostatic Vapor Ablation

• Registration Number: NCT03605745
• Lead Sponsor: Boston Scientific Corporation

Brief Summary

Prospective, multicenter, single arm clinical trial designed to evaluate the safety of the Rezūm System in treating subjects with symptomatic BPH for prostate sizes \>80cm3 and ≤150 cm3.

Detailed Description

A prospective, multicenter, single arm clinical trial designed to evaluate the safety of the Rezūm System in treating subjects with symptomatic BPH for prostate sizes \>80cm3 and ≤150 cm3.

Study Timeline

• Study Start: 2018-06-19
• Study First Submitted: 2018-07-23
• Study First Submitted QC: 2018-07-23
• Study First Posted: 2018-07-30
• Primary Completion: 2020-06-25
• Study Completion: 2020-08-11
• Results First Submitted: 2021-06-04
• Status Verified: 2021-07
• Results First Submitted QC: 2021-07-19
• Last Update Submitted: 2021-07-19
• Results First Posted: 2021-08-10
• Last Update Posted: 2021-08-10

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Male
• Target Recruitment: 47

Inclusion Criteria

1. Male subjects ≥ 50 years of age who have symptomatic BPH.
2. International Prostate Symptom Score (IPSS) score ≥ 13.
3. Peak urinary flow rate (Qmax): ≥ 5ml/sec to ≤ 12 ml/sec with minimum voided volume of ≥ 125 ml.
4. Post-void residual (PVR) ≤300 ml.
5. Prostate volume >80 cm3 to ≤150 cm3

Exclusion Criteria

Urology:

1. Any prior invasive prostate intervention (e.g., "Radiofrequency" thermotherapy, balloon, microwave thermotherapy, "Prostatic Urethral Lift", "Transurethral Resection", or laser) or other surgical interventions of the prostate.

2. Undergone a prostate biopsy within 60 days prior to the scheduled treatment date or has an imminent need for surgery.

3. Verified acute bacterial prostatitis within last 12 months documented by culture.

4. Active or history of epididymitis within the past 3 months.

5. Urethral strictures, bladder neck contracture, unusual anatomy or muscle spasms that would prevent the introduction and use of the Rezūm device.

6. Diagnosed bladder, urethral or ureteral stones or active stone passage in the past 6 months, provided that stones that are known to be in the kidney and have been stable for a period exceeding 3 months are permissible.

7. Subject interested in maintaining fertility.

8. Use of the following medications where the dose is not stable (stable dose defined as the same medication and dose in the last three months):

   1. Beta-blockers;
   2. Anticonvulsants;
   3. Antispasmodics;
   4. Antihistamines;
   5. Alpha blockers for BPH and anticholinergics or cholinergics;
   6. Type II, 5-alpha reductase inhibitor (e.g., finasteride (Proscar, Propecia));
   7. Dual 5-alpha reductase inhibitor (e.g., dutasteride (Avodart));
   8. Estrogen, drug-producing androgen suppression, or anabolic steroids;
   9. PD5 Inhibitors (e.g., Viagra, Levitra or Cialis)

9. Subjects who have had an incidence of spontaneous urinary retention either treated with indwelling transurethral catheter or suprapubic catheter 6 months prior to baseline. A provoked episode now resolved is still admissible

10. Evidence of atonic neurogenic bladder evaluated by a baseline urodynamic assessment.

11. Visible hematuria with subject urine sample without a known contributing factor.

12. Presence of a penile implant or stent(s) in the urethra or prostate

13. Active urinary tract infection by culture within 7 days of treatment or two documented independent urinary tract infections of any type in the past 6 months.

    Gastroenterology:

14. Previous pelvic irradiation or radical pelvic surgery.

15. Previous rectal surgery (other than hemorrhoidectomy) or known history of rectal disease.

    Nephrology:

16. Compromised renal function defined as serum creatinine > 2.0 mg/dl.

17. Hydronephrosis (Grade 2 or higher).

    Oncology:

18. Prostate cancer testing:

    If PSA is > 2.5 ng/ml and ≤ 10 ng/ml with free PSA <25%, prostate cancer for the subject must be/had been ruled out through a negative biopsy prior to enrollment

    • Males 50-59 years - PSA is >2.5 ng/ml and ≤10 ng/ml with free PSA <25%,
    • Males 60+ years - PSA is >4 ng/ml and ≤10 ng/ml, with free PSA <25%

19. History of confirmed malignancy or cancer of the prostate or bladder; however, high grade prostatic intraepithelial "PIN" is acceptable.

20. History of cancer in non-genitourinary system that is not considered cured (except basal cell or squamous cell carcinoma of the skin). A potential participant is considered cured if there has been no evidence of cancer within five years of enrollment.

    Cardiology:

21. History of clinically significant congestive heart failure (i.e., NYHA Class III and IV).

22. Cardiac arrhythmias that are not controlled by medication and/or medical device.

23. An episode of unstable angina pectoris, a myocardial infarction, transient ischemic attack, or a cerebrovascular accident within the past six months.

    Pulmonology:

24. History of significant respiratory disease where hospitalization for the disease is required.

    Hematology:

25. Diagnosed or suspected bleeding disorder, or coagulopathies.

26. Use of antiplatelet or anticoagulant medication except low dose aspirin (<100mg/day) within 10 days prior to treatment.

    Endocrinology:

27. History of diabetes not controlled by a stable dose of medication over the past three months, provided that patients with a hemoglobin A1c <8.0% are allowed.

    Immunology:

28. History of immunosuppressive conditions (e.g., AIDS, post-transplant).

    Neurology:

29. Any cognitive or psychiatric condition that interferes with or precludes direct and accurate communication with the study investigator regarding the study or affect the ability to complete the study quality of life questionnaires.

30. Diagnosed or suspected primary neurologic conditions such as multiple sclerosis or Parkinson's disease or other neurological diseases known to affect bladder function, sphincter function or poor detrusor muscle function (< 25% of accepted and established nomograms).

    General:

31. Currently enrolled in any other pre-approval investigational study in the US (does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints (e.g., limit use of study-required medication, etc.).

32. Any significant medical history that would pose an unreasonable risk or make the subject unsuitable for the study.

33. Inability to provide a legally effective "Informed Consent Form" and/or comply with all the required follow-up requirements.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment	Prostatic Vapor Ablation	Prostatic Vapor Ablation with Rezum

Primary Outcome Measures

Name	Time	Method
Number of Participants With ≥ 30% Improvement in Symptoms as Measured by the International Prostate Symptom Score (IPSS)	6 Months	The proportion of the intent-to-treat (ITT) analysis population that responds to the Rezum therapy is reported. A responder is defined as a subject who has an improvement in International Prostate Symptom Score (IPSS) \> 30% from baseline to 6 months post-therapy. IPSS scores range from 0 (no symptoms) to 35 (severe symptoms). Improvement in symptoms is shown by a reduction in score.
Number of Participants With Post Procedure Device Related Serious Complications	6 Months	Assess the composite rate of post procedure device related serious complications in treated subjects through 6 months follow-up.

Secondary Outcome Measures

Name	Time	Method
Number of Subjects With Device-related Retention Catheterizations	6 Month	This safety endpoint will be to characterize the rate of post procedure device-related serious retention catheterizations at 6 months.
Change in Lower Urinary Tract Symptoms as Assessed by the Absolute Change in IPSS Score From Baseline to Follow-up	Baseline, 6 weeks, 3 months, 6 months, 1 year	The change in IPSS from baseline to each follow-up visit was determined. IPSS scores range from 0 (no symptoms) to 35 (severe symptoms). Improvement in symptoms is shown by a reduction in score.

Trial Locations

Locations (10)

Houston Metro Urology; 🇺🇸 Houston, Texas, United States

Jersey Urology Group; 🇺🇸 Somers Point, New Jersey, United States

Pinellas Urology, LLC; 🇺🇸 Saint Petersburg, Florida, United States

Arizona Urology Specialists; 🇺🇸 Scottsdale, Arizona, United States

First Urology, PSC; 🇺🇸 Jeffersonville, Indiana, United States

Adult & Pediatric Urology, P.C.; 🇺🇸 Omaha, Nebraska, United States

Sydney Adventist Hospital/University of Sydney; 🇦🇺 Wahroonga, New South Wales, Australia

Urology San Antonio; 🇺🇸 San Antonio, Texas, United States

Chesapeake Urology Associates, LLC; 🇺🇸 Towson, Maryland, United States

University of Kansas Medical Center; 🇺🇸 Kansas City, Kansas, United States